An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents
Authors
Keywords
NSCLC, Pretreated patients, ErbB Family Blocker, Multityrosine kinase inhibitors, Anti-angiogenic agents
Journal
Clinical & Translational Oncology
Volume 15, Issue 5, Pages 343-357
Publisher
Springer Nature
Online
2013-01-28
DOI
10.1007/s12094-012-0964-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501
- (2017) J. H. Schiller et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC
- (2017) P. A. Janne et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).
- (2017) J. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
- (2017) B. Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).
- (2017) M. J. Boyer et al. JOURNAL OF CLINICAL ONCOLOGY
- An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
- (2017) G. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).
- (2017) N. Yamamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.
- (2017) J. Von Pawel et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.
- (2017) Y. Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).
- (2017) S. M. Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
- (2017) Marina Chiara Garassino et al. JOURNAL OF CLINICAL ONCOLOGY
- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
- (2011) E. Felip et al. ANNALS OF ONCOLOGY
- A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
- (2011) M. Reck et al. ANNALS OF ONCOLOGY
- The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers
- (2011) Carlo L. Bello et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- (2011) P. A. Janne et al. CLINICAL CANCER RESEARCH
- Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size
- (2011) Tom Donnem et al. Clinical Lung Cancer
- Afatinib (BIBW 2992) development in non-small-cell lung cancer
- (2011) Vera Hirsh Future Oncology
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Richard H. de Boer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
- (2010) P. M. Ellis et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
- (2010) H. J. Ross et al. CLINICAL CANCER RESEARCH
- Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
- (2010) Hester van Cruijsen et al. EUROPEAN JOURNAL OF CANCER
- BIBF 1120 for the treatment of non-small cell lung cancer
- (2010) Martin Reck EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sorafenib: a clinical and pharmacologic review
- (2010) Renuka Iyer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer
- (2010) Nasser Altorki et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
- (2010) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer
- (2010) Myung Hee Chang et al. LUNG CANCER
- Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2010) I. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer
- (2009) T. Donnem et al. ANNALS OF ONCOLOGY
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
- (2009) S Novello et al. BRITISH JOURNAL OF CANCER
- Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer
- (2009) G. R. Blumenschein et al. CLINICAL CANCER RESEARCH
- Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer
- (2009) E. O. Hanrahan et al. CLINICAL CANCER RESEARCH
- A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
- (2009) K.-K. Wong et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
- (2009) Joan H. Schiller et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
- (2009) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer
- (2009) Emer O. Hanrahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?
- (2009) Mario Scartozzi et al. LUNG CANCER
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group
- (2008) Glenwood Goss et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2008) John V. Heymach et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
- (2008) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More